PerkinElmer, Inc., (NYSE: PKI), a worldwide leader committed to innovating for a healthier world, today launched the Cellaca® PLX Image Cytometry System, a first-of-its-kind benchtop platform that allows researchers to evaluate multiple Critical Quality Attributes (CQAs) of cell samples in a single automated workflow, including cell identity, quality and quantity.
The cutting-edge Cellaca PLX system, designed by the corporate’s Nexcelom unit, combines best-in-class image cytometer hardware, software, validated consumables and trackable data reporting multi functional system without requiring complex calibration procedures or intense training requirements. To further streamline the shopper experience, optimized reagent kits with validated antibodies from PerkinElmer’s BioLegend business are also a part of the proprietary solution.
The brand new offering provides researchers expanded cell sample CQA evaluation options beyond flow cytometry and marking methods, which historically have required a wide range of different instruments and analytical methods. By combining these capabilities, researchers can now detect multiple markers concurrently (multiplexing) and perform immunophenotyping and viability assays in seconds with an easy-to-use, modern user interface.
Pharmaceutical corporations have invested heavily in cell and gene therapy, but they struggle to evaluate the complex cell samples required to fulfill immense scientific demands and regulatory rigor across their research and manufacturing processes,”
Alan Fletcher, senior vice chairman, Life Sciences, PerkinElmer.
“While the Cellaca PLX Image Cytometer platform is therapeutic area agnostic, it is anticipated to be especially helpful for researchers working in CAR-T cell therapy who need to streamline their phenotyping of immune cells for downstream processes.”
PerkinElmer’s Nexcelom unit is a number one provider of automated cell counting technology and image cytometry products for cell evaluation, including the unique and widely adopted Cellaca® MX high-throughput automated cell counter. Learn more in regards to the latest platform and other image cytometry instruments and reagents at BioProcessing International East from September 27-30 in Boston where PerkinElmer is showcasing the most recent innovations across its extensive Life Science and cell and gene therapy portfolio in booths 625 and 631. Product demonstrations will be scheduled here.
About PerkinElmer
PerkinElmer is a number one, global provider of end-to-end solutions that help scientists, researchers and clinicians higher diagnose disease, discover latest and more personalized drugs, monitor the security and quality of our food, and drive environmental and applied evaluation excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, our dedicated team of greater than 16,000 collaborates closely with business, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that speed up workflows, deliver actionable insights and support improved decision making.
We’re also deeply committed to good corporate citizenship through our dynamic ESG and sustainability programs. The Company reported revenues of roughly $5.0 billion in 2021, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is out there at www.perkinelmer.com. Follow PerkinElmer on LinkedIn, Twitter, Facebook, Instagram, and YouTube.